Distinct DNA Methylation Profiles in Ovarian Tumors: Opportunities for Novel Biomarkers

• Main Authors: Lorena Losi, Sergio Fonda, Sara Saponaro, Sonia T. Chelbi, Cesare Lancellotti, Gaia Gozzi, Loredana Alberti, Luca Fabbiani, Laura Botticelli, Jean Benhattar
• Format: Article
• Language: English
• Published: MDPI AG 2018-05-01
• Series: International Journal of Molecular Sciences
• Subjects: ovarian carcinoma; DNA methylation profiling; Wnt pathway; DNA damage repair system; TERT; MGMT; BRCA1; MLH1; OSMR; ESR1; FOXL2
• Online Access: http://www.mdpi.com/1422-0067/19/6/1559

Aberrant methylation of multiple promoter CpG islands could be related to the biology of ovarian tumors and its determination could help to improve treatment strategies. DNA methylation profiling was performed using the Methylation Ligation-dependent Macroarray (MLM), an array-based analysis. Promoter regions of 41 genes were analyzed in 102 ovarian tumors and 17 normal ovarian samples. An average of 29% of hypermethylated promoter genes was observed in normal ovarian tissues. This percentage increased slightly in serous, endometrioid, and mucinous carcinomas (32%, 34%, and 45%, respectively), but decreased in germ cell tumors (20%). Ovarian tumors had methylation profiles that were more heterogeneous than other epithelial cancers. Unsupervised hierarchical clustering identified four groups that are very close to the histological subtypes of ovarian tumors. Aberrant methylation of three genes (BRCA1, MGMT, and MLH1), playing important roles in the different DNA repair mechanisms, were dependent on the tumor subtype and represent powerful biomarkers for precision therapy. Furthermore, a promising relationship between hypermethylation of MGMT, OSMR, ESR1, and FOXL2 and overall survival was observed. Our study of DNA methylation profiling indicates that the different histotypes of ovarian cancer should be treated as separate diseases both clinically and in research for the development of targeted therapies.